MIRA
INFORM REPORT
|
Report Date : |
10.12.2007 |
IDENTIFICATION
DETAILS
|
Name : |
INTAS PHARMACEUTICALS LIMITED |
|
|
|
|
Formerly Known As : |
INTAS LABORATORIES PRIVATE LIMITED |
|
|
|
|
Registered Office : |
2nd Floor,
Chinubhai Centre, Off Nehru Bridge, Ashram Road, Ahmedabad – 380 009, Gujarat |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.03.2006 |
|
|
|
|
Date of Incorporation : |
31.05.1985 |
|
|
|
|
Com. Reg. No.: |
04-7866 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24231GJ1985PTC007866 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
AHMI00350A |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAACI5120L |
|
|
|
|
Legal Form : |
A closely held public
limited liability company |
|
|
|
|
Line of Business : |
Manufacturing and Exporting of Medical Formulations in the key
Therapeutic Segments of Cardiovascular, Neuropsychiatry, Gastroenterological,
Antibacterial and Dermatological Products. |
RATING &
COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 7400000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well
established and one of the fastest growing pharmaceutical companies in India.
The company’s track records are fine. Banking relations are good. The company
is making steady progress in its turnover and profits and products line.
Trade relations are fair. Payments are usually correct and as per
commitments. The company can
be considered good for business dealings at usual trade terms and conditions.
|
LOCATIONS
|
Registered Office : |
2nd
Floor, Chinubhai Centre, Off Nehru Bridge, Ashram Road, Ahmedabad – 380 009,
Gujarat, India |
|
Tel. No.: |
91-79-26576655 / 26579052 / 26578269 |
|
Fax No.: |
91-79-26588862 / 26578862 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory 1 : |
Plot No. 457/458
, Sarkhej - Bavla Highway, Village: Matoda - 382210, Taluka: Sanand,
Ahmedabad, Gujarat, INDIA |
|
Tel. No.: |
91-2717-551111/551298 |
|
Fax No.: |
91-2717-551106 |
|
|
|
|
Factory 2 : |
7/3 GIDC Estate, B/H Dena Bank, Vatva, Ahmedabad- 382445, Gujarat,
India |
DIRECTORS
|
Name : |
Mr. Hasmukh K.
Chudgar |
|
Designation : |
Chairman and Managing Director |
|
Address : |
3, Sanidhya Bunglows, Near Someshwar Jain Temple, Satelite, Ahmedabad
– 380015, Gujarat, India |
|
Date of Birth/Age : |
16.06.1933 |
|
Qualification : |
B. Pharma |
|
Date of Appointment : |
31.05.1985 |
|
|
|
|
Name : |
Dr. Urmish
Chudgar |
|
Designation : |
Director |
|
Address : |
16, Nishant Bunglows, Satelite, Ahmedabad – 380015, Gujarat, India |
|
Date of Birth/Age : |
16.02.1959 |
|
Qualification : |
M.D. - Oncology & Hematology |
|
Date of Appointment : |
30.09.1996 |
|
|
|
|
Name : |
Mr. Nimish H. Chudgar
|
|
Designation : |
Director |
|
Address : |
3, Sanidhya Bunglows, Near Someshwar Jain Temple, Satelite, Ahmedabad
– 380015, Gujarat, India |
|
Date of Birth/Age : |
19.07.1960 |
|
Qualification : |
B.Sc. |
|
Date of Appointment : |
31.05.1985 |
|
|
|
|
Name : |
Mr. Binish H.
Chudgar |
|
Designation : |
Director (International Business) |
|
Address : |
12, Aristo Villa, Opposite Gold Coin Complex, Satillite, Jodhpur Char
Rasta, Ahmedabad – 380015, Gujarat, India |
|
Date of Birth/Age : |
01.12.1963 |
|
Qualification : |
B. Com., MBA |
|
Date of Appointment : |
31.05.1985 |
|
|
|
|
Name : |
Mr. Smivasa Rao L. Aluri |
|
Designation : |
Nominee Director |
|
Address : |
C/o ICICI Venture Funds Mgt. Company Limited, Stanrose House, Ground Floor,
Appasaheb, Marathe Marg, Prabhadevi, Mumbai, Maharashtra, India |
|
Date of Birth/Age : |
13.02.1965 |
|
Date of Appointment : |
16.07.2004 |
KEY EXECUTIVES
|
Name : |
Mr. Dipesh R.
Shah |
|
Designation : |
Company Secretary
|
|
Address : |
53, Vrundavan
Bunglows, Opposite Someshwara Temple, Satellite Ring Road, Ahmedabad,
Gujarat, India |
|
Date of Birth/Age : |
31.08.1977 |
|
Date of Appointment : |
02.08.2004 |
|
|
|
|
Name : |
Mr. Manoj
Narayanan Nair |
|
Designation : |
Company Secretary
|
|
Address : |
“Laxmi Nivas”
648-1, Sector – 4, C Gandhinagar - 382006, Gujarat, India |
|
Date of Birth/Age : |
20.10.1979 |
|
Date of Appointment : |
08.06.2007 |
|
|
|
|
Name : |
Mr. Mani Iyer |
|
Designation : |
Senior Vice
President (Finance & Corporate Affairs) |
|
|
|
|
Name : |
Dr. R. C. Rane |
|
Designation : |
Vice President –
Medical Services |
|
|
|
|
Name : |
Dr. A. P. Mamtani |
|
Designation : |
Vice President-
Veterinary – Marketing & Sales |
|
|
|
|
Name : |
Mr. M. N.
Bhattacharya |
|
Designation : |
Senior Vice
President – International Marketing |
|
|
|
|
Name : |
Dr. P. G.
Shrotriya |
|
Designation : |
Senior Vice
President – Operations |
|
|
|
|
Name : |
Dr. Kashmira
Pagdiwalla |
|
Designation : |
Vice President –
Human Resources |
|
|
|
|
Name : |
Mr. Jayesh Shah |
|
Designation : |
Vice President –
Finance & Accounts |
MAJOR SHAREHOLDERS
/ SHAREHOLDING PATTERN
|
Names of Shareholders |
|
No. of Shares |
|
Nimish H Chudgar |
|
313054 |
|
Binish H Chudgar |
|
301874 |
|
Umish H Chudgar |
|
5010 |
|
Kusumben H Chudgar |
|
91665 |
|
Bindiben B Chudgar |
|
172325 |
|
Parulben U Chudgar |
|
176090 |
|
Binaben N Chudgar |
|
101145 |
|
Hasmukh K Chudgar |
|
174683 |
|
Equatorial Private Limited |
|
2310000 |
|
Unit Trust of India A/c Vecaus – I |
|
581055 |
|
Intas Finance Private Limited |
|
200000 |
|
Shail U Chudgar |
|
233099 |
|
Total |
|
4660000 |
|
|
|
|
|
Equity Share
Breakup |
|
Percentage of
Holding |
|
Category |
|
|
|
Foreign holdings [Foreign institutional investors, Foreign Companies, Foreign Financial Institutions, Non-resident Indian or Overseas corporate bodies or others] |
|
12.47 |
|
Bodies corporate |
|
53.86 |
|
Directors or relatives of directors |
|
33.67 |
|
Total |
|
100.00 |
List of Allottes
|
Names of Allottees |
|
No. of Shares |
|
Kusumebn H. Chudgar |
|
17475 |
|
Binaben N. Chudgar |
|
17475 |
|
Bindien B. Chudgar |
|
17475 |
|
Parulben U Chudgar |
|
17475 |
|
Total |
|
69900 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturing and Exporting of Medical Formulations in the key
Therapeutic Segments of Cardiovascular, Neuropsychiatry, Gastroenterological,
Antibacterial and Dermatological Products. |
|
|
|
|
Products : |
v
Tablets v
Injectables v
Capsules v
Bulk Drugs |
|
|
|
|
Exports : |
|
|
Countries : |
Kenya, Tanzania,
Trinidad, Thailand, Mauritius, Sri Lanka, Malaysia, Russia, Netherlands, UK
and West Indies. |
|
|
|
|
Imports : |
|
|
Countries : |
Trinidad, Mauritius,
Sri Lanka, Europe, USA, Italy, Germany, Spain and Hong Kong |
|
|
|
|
Terms : |
|
|
Purchasing : |
L/C, D/A and CAD
terms |
GENERAL
INFORMATION
|
Suppliers : |
|
|
|
|
|
Customers : |
|
|
|
|
|
No. of Employees : |
515 |
|
|
|
|
Bankers : |
|
|
|
|
|
Banking
Relations : |
Satisfactory |
|
|
|
|
Auditors : |
|
|
Name : |
Apaji Amin and
Company Chartered
Accountants |
|
Address : |
304, Aakansha, Navrangpura,
Ahmedabad - 380 009, Gujarat, India |
|
Tel. No.: |
91-79-2303603 |
|
|
|
|
Associates/Subsidiaries : |
Intas Exports Active in the
export of medical formulations to Europe, Asia Pacific and Africa International
Pharmaceuticals Subject is a proprietory
concern. Engaged as
Manufacturer Viresh
Corporation Subject is a
proprietory concern. Acts as traders Intas
Distributors Subject is a
proprietory concern. Acts as traders Zen Enterprises Subject is a
proprietory concern. Acts as traders BNB Enterprises Subject is a
proprietory concern. Acts as traders Astron Packaging
Limited Astron Research
Limited Equatorial
Private Limited Lambda
Therapeutic Research Limited Epsilon Marketing
and Consultancy Private Limited Intas Finance Private
Limited Celestial
Biological Limited Advanced
Transfusion Medicine Research Foundation One Advertising
and Communication Services Limited Cytas Research
Limited |
|
|
|
|
Subsidiaries : |
|
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
10,000,000 |
Equity Shares |
Rs. 10/- each |
Rs. 100.000 millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
4660000 |
Equity Shares |
Rs. 10/- each |
Rs. 46.600 Millions |
FINANCIAL DATA
[all figures are in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
46.600 |
46.600 |
40.100 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
1793.218 |
1610.764 |
952.816 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
1839.818 |
1657.364 |
992.916 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
1189.805 |
1161.368 |
1137.988 |
|
|
2] Unsecured Loans |
221.560 |
222.579 |
83.586 |
|
|
TOTAL BORROWING |
1411.365 |
1383.947 |
1221.574 |
|
|
DEFERRED TAX LIABILITIES |
239.788 |
301.909 |
225.628 |
|
|
|
|
|
|
|
|
TOTAL |
3490.971 |
3343.220 |
2440.118 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
1655.738 |
1691.039 |
1061.210 |
|
|
Capital work-in-progress |
0.896 |
245.006 |
202.520 |
|
|
|
|
|
|
|
|
INVESTMENT |
173.501 |
84.105 |
68.719 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
1241.082
|
948.901
|
858.684 |
|
|
Sundry Debtors |
800.856
|
598.163
|
526.933 |
|
|
Cash & Bank Balances |
120.954
|
66.817
|
79.966 |
|
|
Other Current Assets |
0.000
|
0.000
|
0.000 |
|
|
Loans & Advances |
556.465
|
354.435
|
177.018 |
|
Total Current Assets |
2719.357 |
1968.316
|
1642.601 |
|
|
Less : CURRENT LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
1013.368
|
622.271
|
540.212 |
|
|
Provisions |
50.993
|
39.762
|
22.484 |
|
Total Current Liabilities |
1064.361 |
662.033
|
562.696 |
|
|
Net Current Assets |
1654.996 |
1306.283
|
1079.905 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
5.840 |
16.787 |
27.764 |
|
|
|
|
|
|
|
|
TOTAL |
3490.971 |
3343.220 |
2440.118 |
|
PROFIT & LOSS
ACCOUNT
|
PARTICULARS |
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
Sales Turnover |
6204.400 |
4543.200 |
3788.470 |
|
Other Income |
72.130 |
55.820 |
37.230 |
|
Total Income |
6276.530 |
4599.020 |
3825.700 |
|
|
|
|
|
|
Profit/(Loss) Before Tax |
543.530 |
394.400 |
325.176 |
|
Provision for Taxation |
89.520 |
109.300 |
95.486 |
|
Profit/(Loss) After Tax |
452.570 |
285.100 |
229.690 |
|
|
|
|
|
|
Expenditures : |
|
|
|
|
Total Expenditure |
5733.000 |
4085.400 |
3561.151 |
KEY RATIOS
|
PARTICULARS |
|
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
PAT / Total Income |
(%) |
7.21
|
6.20 |
6.00 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
8.76
|
8.68 |
8.58 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
12.42
|
10.78 |
12.03 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.30
|
0.24 |
0.33 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
1.35
|
1.23 |
1.80 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.55
|
2.97 |
2.92 |
LOCAL AGENCY
FURTHER INFORMATION
HISTORY
The company was
incorporated on 31st May 1985 at Ahmedabad in Gujarat under the name
and style of Intas Laboratories Private Limited having Company Registration
Number 7866. It became a deemed public
limited liability company with effect from 29.03.1995.
The name was
changed to the present somewhere in the year 1996.
The Group commenced
with trading activity in 1964 and went into manufacturing in the year
1976.
The unit no. 2 at
Matoda on Sarkhej Bavla Highway is a Rs. 150 millions project for manufacturing
of all range of pharmaceutical formulations and bulk drugs.
The plant at Vatva
was functioning on a loan lease basis from 13.07.1999.
With the leadership
in the field of gastroenterology and neuro-psychiatry, the company has become
one of the leading pharmaceuticals groups in India since 1976.
With a strong
Formulation Development facility, several innovative formulations have been
developed for the first time in India which include Nilol (Film Coated Tablets
of Nifedipine Sustained Release 20 mg + Atenolol 50 mg), Zolax – SR (Sustained
Release tablets of Alprazolam 1.5 mg), Ciza-MPS (The latest prokinetic
cisapride + Simethicone), Zen Retard (Controlled Release formulation of
Carbamazepine) and Nimotas – CD (Nimesulide tablets in Chewable + Dispersible
form).
Subjects strength
is its strong R&D and Modern packaging to suit customers requirements.
Several products like Mefloqiune, Amlodipine, Naltrexone & Lomefloxacin are
available in coldforming ALU-ALU packs.
It is in trade
terms with:
v
Chemo Iberica
S.P.A., Spain
v
Chumann Pharma
GmbH, Germany
v
Bayron
Chemicals, USA
v
Laboratory Mag
S.P.A., Milano, Italy
v
Vis
Pharmaceuticals, Italy
v
Vertex
Chemicals, Hong Kong
v
Trinpharma
Company, Trinidad
v
Fair Trade,
Mauritius
v
Thron Group
Private Limited, Sri Lanka
v
Dr. Reddy’s
Laboratories, Hyderabad, Andhra Pradesh, India
v
Bharat Biotech
International Limited, Hyderabad, Andhra Pradesh, India
v
Shashun Drugs
& Chemicals Limited, Chennai, Tamil Nadu, India
v
Hetero Drugs
Limited
The company is a
Registered Small Scale Industry.
It has launched
'Typho-Vi, a typhoid vaccine and a high-tech oncology segment with Cytax, anti
cancer product, which was introduced in collaboration with Samyang of
Korea.
Neovet - The
veterinary division of the company ranks among the top 25 animal healthcare
companies in India. It launched
Mammitel, an anti-mastitis drug in collaboration with Biove Laboratories of
France.
Neovet, the animal
healthcare division of Intas
projects the vision of the new millenium and aims at a perfect partnership with
veterinary profession and farming community.
With the
introduction of the highest quality formulations for a variety of ailments of
large and small animals, it has already made a significant progress in the
Indian Veterinary Pharmaceutical Market.
Professional ethics and relationship is the hallmark of Neovet as it strives to
understand the basic needs of the veterinarians, farmers, business partners and
its employees.
In the international market the company has presence in more than 30 countries
and during the year the company made 200 submissions and registered 61
additional products in 15 countries.
The company has
tie-up with Sanofi Winthrop Limited.
The company is
exclusively focusing on the specialised cardiovascular, neurological and
gastroenterological therapeutic segments and achieving a leadership position in
these key segments.
The company has
strategic alliance with :
- MEB, The Netherlands
- TGA, Australia
- MCC, South Africa
- MCA, UK for veterinary products
- AFI, Belgium
- FDA, Nordic Countries
- Anvisa, Brazil
Bankers Charges
Report as per Registry
|
Name of the company |
INTAS
PHARMACEUTICALS LIMITED |
|
Presented By |
Mr. Mani Iyer |
|
1) Date and description of instrument creating the change |
Unattestted Deed
of Hypothecation dated 25.11.1998 executed by Intas Pharmaceuticals Limited
in favour of Export – Import Bank of India |
|
2) Amount secured by the charge/amount owing on the securities of charge |
Loan of Rs.
22.400 Millions including any converted Rupee amount of foreign currency loan
together with interest, compound interest, additional interest by way of liquidated
damages costs, charges expenses and all other monies payable by the borrower
to Exim Bank under the loan agreement dated the November 25, 1998 made
between the borrower and the EXIM Bank.
|
|
3) Short particular of the property charged. If the property acquired is subject to charge, date of the acquired of the property should be given |
The whole of the
Borrower’s moveable fixed assets of the Clinical Research Centre both present
and future including Moveable plant and
machinery, equipment, appliances, furniture, vehicles, machinery, spares and
stores, tools and accessories whether or not installed and Related moveable
in the course of transit or delivery whether now belonging or which may
hereafter belong to the borrower or which may be held by any person at any
place within or outside India to the order or disposition of the borrow and
all documents of including bills of lading policies of insurance and other
instruments and documents relating to such moveable together with benefits of
all rights thereto. |
|
4) Gist of the terms and conditions and extent and operation of the charge. |
The charge
created by the aforesaid deed of hypothecation shall operate as a continuing
security by way of the first / second / exclusive charge for the due
repayment by the borrower to EXIM Bank of the loan of Rs. 22.400 Millions
together with payment of interest, compound interest, additional interest by
way of liquidated damages charges, expenses and all other monies payable by
the borrower to EXIM Bank in terms of the said loan agreement. The said charge
shall rank in the order of priority set out in Schedule IV to the deed of
Hypothecation. |
|
5) Name and Address and description of the person entitled to the charge. |
Export – Import
Bank of India Centre One, World
Trade Centre Cuffe Parade,
Mumbai – 400005 |
|
6) Date and brief description of instrument modifying the charge |
-- |
|
7) Particulars of modifications specifying the terms and conditions or the extent of operations of the charge in which modification is made and the details of the modification. |
-- |
|
This form is for |
Creation of
charge |
|
Corporate
identity number of the company |
U24231GJ1985PTC007866 |
|
Name of the
company |
INTAS PHARMACEUTICALS LIMITED |
|
Address of the
registered office or of the principal place of business in India of the company |
2nd
Floor, Chinubhai Centre, Off Nehru Bridge, Ashram Road, Ahmedabad – 380 009,
Gujarat, India |
|
Type of charge |
Movable Property |
|
Particular of
charge holder |
ICICI Bank Limited Landmarkrace Cource Circle Alkapuri, Baroda – 390015, Gujarat, India |
|
Nature of
description of the instrument creating or modifying the charge |
Deed of
hypothecation dated June 1, 2007 executed at Ahmedabad by Intas
Pharmaceuticals Limited in favour of ICICI Bank Limited |
|
Date of
instrument Creating the charge |
01.06.2007 |
|
Amount secured by
the charge |
Rs. 602.000
Millions |
|
Brief particulars
of the principal terms an conditions and extent and operation of the charge |
Rate of Interest The aggregate of
: The applicable
Margin [1.30 % p.a.] and 6 months LIBOR Terms of
repayment In 8 equal annual
installments, first installment being due on the end of the 18 months from
the first drawdown date. Margin 1.30 % p.a. |
Fixed
Assets
v
Land
v
Building
v
Plant and
machinery
v
Furniture
& Fixture
v
Office
equipment
v
Vehicle
v
Computers
As per Website
Details:
Genesis
Decades ago, an enterprising young Medical Representative, H
K Chudgar, dreamt of providing quality healthcare products to his country. At a
time when India imported even foodgrains, this visionary wanted to manufacture
world class medicines in the country. Armed with a degree in Pharmacy, this
budding entrepreneur set up shop as a pharma trading agency in the 1960s and
thus was Intas born.
Intas growth chart
|
1960s |
International Trading Agency, the genesis of Intas |
|
1970s |
Vatva plant, a small scale manufacturing unit |
|
1980s |
National distribution channel set up First successful molecule launched |
|
1990s |
Consolidation and expansion Leadership in the domestic market Entry into the international market |
Never one to tread the beaten path, Mr. H K Chudgar
decided to focus on niche therapeutic segments at a time when all others
concentrated on the mass markets. Success for Intas came in the form of an anti-depressant
that took the medical community by storm and then there was no looking back!
Mr. Nimish Chudgar, Mr. Binish Chudgar and Dr. Urmish
Chudgar joined the management team and together they led Intas into the
psychiatric, neurological, cardiac and gastroenterological segments. So
successful was this strategy of focusing on speciality segments that today
Intas is among the fastest growing pharmaceutical companies in India.
As Intas grew and diversified into newer areas, Mr. H
K Chudgar brought in a professional management team to help implement his
Vision and today Intas reaps the twin benefits of entrepreneurial vision and
professional management. This dynamic leadership has set the agenda for growth
and Intas has been achieving an average annual growth of over 30% since 1990
with the turnover crossing the Rs. 1000 million mark in 1999. At the end of the
financial year in 2001 it has increased to Rs. 1800 million.
Intas today
Subject is among the fastest growing pharmaceutical
companies in India. They have been meteorically progressing up the ORG-MAT
rankings, the barometer of success in the Indian pharmaceutical industry. They
have jumped from the 49th rank in end of 1998 to 24th position today.
Quality Procedure
Quality is a not a departmental obligation. It is
significant to everything and everyone in the organisation. To ensure Total
Quality Management, the Quality Assurance (QA) department in their factory is
autonomous in its functioning.
In-house quality checks, which are detailed in their
Standard Operating Procedures (SOP), have been drawn up in addition to the
recommendations specified in the US, British & Indian Pharmacopoeias for
each of their operations commencing from the raw material audit to in-process
checks through finished product inspection.
Raw materials are accepted for manufacturing only after it is found to be of
international grade by their in-house and independent laboratories.
Their in-house bio-equivalence centre has been set up
to conduct in-house studies as well as to expedite experiments pursued by
academic and research institutes.
Corporate Culture
Concern for quality is at the core of all their
activities. They aim to improve the quality of life, not only in their own country,
but worldwide. Indeed, they are striving to build a Global Company, a world
leader in life sciences, and to be the very best in each of their activities.
At Intas, they have made innovation a way of life.
Innovation in products; in technology; in packaging; in their business
practices. In the recent years, Intas has introduced into the Indian market
various innovations like new drug delivery systems, extended release molecules,
recombinant vaccines and ALU-ALU packaging.
Fuelling their innovative practices is a genuine
desire to provide customised solutions to suit their customers' needs and to
develop true partnerships with them. They work relentlessly to provide their
customers exactly what they need. With no compromise. And in the process, they
are creating a company where men and women are proud to work and who find in
their work, opportunities commensurate with their commitment.
Facility
Technology Finesse
An obsession to “make the best better” has resulted
in their setting up a highly sophisticated manufacturing plant acclaimed as one
of the finest in South East Asia. This plant is WHO approved and meets US FDA
standards.
The manufacturing speed & capacity of their most
modern plant ensure regular supply of quality drugs to the domestic & international
market. It is equipped with High Efficiency Purified Air (HEPA) technology
which maintains a continuous flow of filtered air inside the plant, thus
providing an absolutely dust free sterile environment. Moreover, the fully
automated facilities, with an electronically monitored environment ensure zero
contamination. They thus successfully extend the benefits of modern technology
to provide newer & better health care services to mankind.
Approved by
v MCA, UK
v TGA, Australia
v MCC, South Africa
v MEB, Netherlands
v AFI, Belgium
v FDA, Nordic Countries
v Anvisa, Brazil
Plant
Details
v Total plot
area: 105,000 sq. m
v Total
Built up area: about 32,000 sq. m
v Total area
of Solid Oral: about 2,100 sq. m
v Total area
of Parenterals: about 2,100 sq. m
Current
Capacity
Ampoules
(1ml to 10 ml): 0.28 million units per day
:: 85 million units per year
Vials: 0.1
million units per day :: 30
million units per year
Manufacturing
Flexibility
Manufacturing
batch sizes from 60 kg to to 1000 kg per batch
Coating
load - from 22 kgs to 300 kgs
Automation of packaging
Semi-automatic Cartonator: Vertopack
Automatic Cartonator
All Cartonator fitted with Leatus
pharma code scanning system for cartons and PILs
In the pipeline…
Setting up a Pallet Manufacturing facility comprising:
- Extruder
- Spheronizer
- Fluid Bed Drier / Wruster
- Fillers
- Dry syrup and Capsules Dosage forms to be manufactured
- Fully functional by February 2004
- Expansion of Oral Solids Manufacturing
Upgraded capacity:
- 18 million units of avg. wt. 500 mg in
a single day
- 5.4 billion units in a year
Strengths
- Well versed in handling contract manufacturing projects for
European companies
- Large capacities to produce bulk quantities of Oral Solids
- Innovative and sophisticated Packaging facilities
- Commitment to Excellence and Quality
- Dedicated and committed team of professionals
- 200 experts in Manufacturing, QC and QA
HRD
Their people will lead us into the next millenium. The
values, ethics, interpersonnel chemistry and congenial work environment makes
this organisation a cohesive, articulate and goal- directed unit.
At Intas, they constantly redefine excellence and
their vision beckons us to forge ahead and achieve higher peaks. Intelligence,
integrity, courage, imagination, self-respect, and a sense of belonging are
qualities not in short supply in their company.
Their culture encourages us to perform Herculean
feats. They set their own goals and constantly strive to surpass them. Their
personal and professional achievements are lauded, and amply rewarded. And if
ever they need a helping hand, their HRD team is ready to support us with
refresher courses and need based training programmes.
In the midst of their achievements, they never forget
that they are a team. They exist not to compete against each other, but strive
together to conquer newer horizons. In their journey to excellence, they take
the time to get to know each other and share a few warm moments.
They are a dynamic team; excited about their basic
purpose; and they share a common set of values. These values, vision, and
mission form the core of their identity; an identity that keeps each Intasian
and the entire Intas team always responsive and innovative in new situations.
Marketing
Domestic Marketing
Intas' marketing set up is geared to cater to the
requirements of different specialty segments.
Intas division markets Gastroenterologicals,
Antibacterials, Dermatologicals, and other related products. It has launched a
recombinant vaccine for Hepatitis B as also a Typhoid vaccine. This division
has various brand leaders e.g. Ciza, Lan-30 and Zopicon.
Altima is the division focussing
exclusively on Neurological and Psychotropic products. Zen, Valprol CR, Zolax
and Risdone feature among its success stories.
Aquila is a recently launched
neuro-psychiatry division operating parallely with Altima. It aims to cater to
the specialised requirements of neurosurgeons and psychiatrists.
Suprima focuses
on the marketing of Cardiovasculars. Among its most successful brands are Amtas
and Monit.
They have made a decisive entry into the hi-tech
oncology segment with their Novatech
division launching Cytax, a revolutionary anti-cancer product. Aloric,
Clogen lozenges and Itaspor capsules are their supportive care products.
Optima, is
focussed at emerging as a leader in the ophthalomology segment. Among its
leading brands are Andre I-kul, Andre Eyedrops and Cyclogyl.
Neovet, their
veterinary division ranks among the top 20 animal healthcare companies in
India. It markets a range of antibiotics, tonics (injectibles), analgesics,
anti-pyretics, corticosteroids, antihistaminics, tranquillisers, and
chemotherapeutic agents. Neovet has launched Mammitel, a pioneering
anti-mastitis drug, in collaboration with Biove Laboratories, France.
Intas Generics
has emerged among the top 10 generic marketers in the Indian pharmaceutical
sector. With its reputation of being a reliable provider of quality products,
the Generics Division is set to exploit the opportunity offered by the emerging
generics market.
Country wide reach
To facilitate easy availability of their brands across the
nation, they have created a countrywide distribution network of C&F agents
& stockists who provide excellent support to the sales personnel. Their
young and dynamic field force of more than 1000 provides us with a strong
national presence.
International Marketing
Intas has an international presence with around 20%
of the current turnover coming from foreign markets, including exports to Latin
America, East Asia, etc. and contract manufacturing for companies in Europe.
Intas intends to enhance its global presence by
leveraging on its technology strengths and the quality of its products. It will
also initiate marketing operations in developed markets with the objective of
achieving a critical mass. Intas is initially exploring marketing tie-ups with
local players of developed markets. It intends to form strategic business units
to spearhead its operations in the US, the UK & the rest of Europe.
Intas
products are available in…
·
Europe
·
Africa
·
Latin American Region
·
South East Asia
·
Russia
·
CIS Countries
Regulatory approvals from...
·
MCA, UK
·
TGA, Australia
·
MCC, South Africa
·
MEB, Netherlands
·
AFI, Belgium
·
FDA, Nordic Countries
·
Anvisa, Brazil
R
& D
Intas has embarked on an intensive program for
development & analytical testing of new formulations including biotech
formulations, with the objective of partnering with top multi-nationals for
formulation research and providing regulatory support. An independent facility,
equipped with modern technology and manned by professionals of the highest
caliber, is the focal point of this initiative.
In the field of transfusion medicine, they have
collaborated with the Technology Development Board (Govt. of India) to develop
two protein derived products - fibrin glue and lyophilized cryoprecpitates.
Innovative
track record
Subject have made innovation a way of life.
Innovation in products, technology and even in packaging. Intas was amongst the
first companies to introduce new drug delivery systems in some of its
formulations (like melt in mouth technology for Domperidone, sustained release
Alprazolam, once daily dosage for Isosorbide5 Mono Nitrate and controlled release
Sodium Valprolate). Intas also brought novel packaging to India through its
investments in ALU-ALU and cold blister packaging technology. Building on these
competencies, they are continuing to be at the forefront of innovation
research.
Strong
formulation development research capabilities
Intas’ current research and development focus on
formulation research. The Formulation research facility is equipped with
equipments identical to those in the manufacturing area, but scaled to
accomodate one-tenth of production batch size. This significantly facilitates
transfer of technology from Research and development to production.
Formulations developed in R&D center are subjected to accelerated stability
testing as per international norms. Analytical research laboratory develops
stability indicating assay methods to analyze related substances and degraded
components.
Enhancing
capabilities in formulation research and development
Intas has embarked on an intensive program for
development & analytical testing of new formulations including biotech
formulations, with the objective of partnering with top multi-nationals for
formulation research and providing regulatory support. An independent facility,
equipped with modern technology and manned by professionals of the highest
caliber, is the focal point of this initiative.
Biotechnology
research
Intas entered the biotech foray in early 2000 with
the vision to establish Intas as a research based manufacturer of quality
biopharmaceuticals and become a significant global player in the bio-generics
market. They are transforming their vision into reality through investments in
human resources and infrastructure. A state-of-the-art research and
manufacturing facility for both bulk and finished biopharmaceutical product
complements the expertise of the multi-disciplinary R&D team with over 15
manyears of international experience.
The first product from this venture is likely to be
launched by late 2003.
Excellence in every aspect
With their committed
approach and their continuing focus on research and innovation, they have
succeeded in bringing international standards to the domestic formulation
market. They have come to be recognised as a dynamic organisation that put up a
world class formulation unit in the shortest possible time and compelled other
companies to benchmark us as excellence in manufacturing.
CMT REPORT
(Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist organization
or whom notice had been received that all financial transactions involving
their assets have been blocked or convicted, found guilty or against whom a
judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction registered
against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or investigation
registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws, regulations
or policies that prohibit, restrict or otherwise affect the terms and
conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.39.38 |
|
UK Pound |
1 |
Rs.80.07 |
|
Euro |
1 |
Rs.57.66 |
SCORE & RATING
EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
7 |
|
PAID-UP CAPITAL |
1~10 |
7 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
7 |
|
--PROFITABILIRY |
1~10 |
7 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
7 |
|
--RESERVES |
1~10 |
7 |
|
--CREDIT LINES |
1~10 |
7 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
63 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|